Answers are grounded in this paper and cite their sources.
Commentary discusses barriers to sustainable innovation in diabetes devices, highlighting regulatory impacts on design efforts.
Reducing the environmental footprint of medical devices used by people with diabetes remains a challenge within the constraints of current regulatory frameworks. These frameworks, which rightly prioritize patient safety, sterility, and traceability, introduce substantial scientific, operational, and legal barriers to sustainable innovation. Efforts to integrate recycled or biodegradable materials, minimize packaging, or redesign products are often impeded by the complexity of revalidation processes, extensive documentation requirements, and a general lack of regulatory precedent. This commentary examines how such structural constraints hinder progress toward sustainable device design, despite mounting evidence of the environmental toll of single-use technologies. It advocates for a strategic shift toward “Design for Sustainability.” Coordinated systemic incentives and regulatory evolution are essential to align sustainability objectives with prevailing safety and quality imperatives.
No takes yet. Share an insight, caveat, or question.
Hossmann et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: